Geron Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Geron Corp.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Geron Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Geron Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Geron Corp. is GERN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Geron Corp. has its primary listing on NASDAQ. You can trade Geron Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Geron Corp. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Geron Corp. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Geron Corp. or others.